EMA/642021/2014

European Medicines Agency decision

P/0290/2014

of 24 October 2014

on the acceptance of a modification of an agreed paediatric investigation plan for eculizumab (Soliris) (EMEA-000876-PIP01-10-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0290/2014

of 24 October 2014

on the acceptance of a modification of an agreed paediatric investigation plan for eculizumab (Soliris) (EMEA-000876-PIP01-10-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/224/2010 issued on 29 October 2010,

Having regard to the application submitted by Alexion Europe SAS on 16 July 2014 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 10 October 2014, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for eculizumab (Soliris), concentrate for solution for infusion, intravenous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Alexion europe SAS, 25 Boulevard de l'Amiral Bruix, 75016 - Paris

France.

Done at London, 24 October 2014

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/459231/2014

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000876-PIP01-10-M01

Scope of the application

Active substance(s):

Eculizumab

Invented name:

Soliris

Condition(s):

Treatment of Paroxysmal Nocturnal Haemoglobinuria

Treatment of Atypical Haemolytic Uraemic Syndrome

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Alexion Europe SAS

Information about the authorised medicinal product:

See Annex II

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Alexion Europe SAS submitted to the European Medicines Agency on 16 July 2014 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/224/2010 issued on 29 October 2010.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 13 August 2014.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

London, 10 October 2014

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition: Treatment of Paroxysmal Nocturnal Haemoglobinuria

The waiver applies to:

- Children from birth to less than 2 years of age
- for concentrate for solution for infusion, intravenous use
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition

Treatment of Paroxysmal Nocturnal Haemoglobinuria

2.1.1. Indication(s) targeted by the PIP

Treatment of Paroxysmal Nocturnal Haemoglobinuria

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Concentrate for solution for infusion

2.1.4. Measures

Area	Number of studies	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	0	Not applicable.
Clinical studies	1	Study 1: Open-label, multicentre, single arm trial to evaluate pharmacokinetic and pharmacodynamic of eculizumab in children from 2 to less than 18 years of age with Paroxysmal Nocturnal Haemoglobinuria.

2.2. Condition

Treatment of Atypical Haemolytic Uraemic Syndrome

2.2.1. Indication(s) targeted by the PIP

Treatment of Atypical Haemolytic Uraemic Syndrome

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.2.3. Pharmaceutical form(s)

Concentrate for solution for infusion

2.2.4. Measures

Area	Number of studies	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	0	Not applicable.
Clinical studies	4	Study 2 Open-label, multicentre, single arm trial to evaluate the effect of eculizumab in adolescents from 12 to less than 18 years of age with weight ≥ 40 kg or more with plasma therapy-resistant Atypical Haemolytic Uraemic Syndrome. Study 3 Open-label, multicentre, single arm trial to evaluate the effect of eculizumab in adolescents from 12 to less than 18 years of age with weight ≥ 40 kg with plasma therapy-sensitive Atypical Haemolytic Uraemic Syndrome. Study 4 Open-label, multicentre, single arm trial to evaluate the efficacy and safety of eculizumab in children from 1 month of age with weight ≥ 5 kg to less than 18 years of age with Atypical Haemolytic Uraemic Syndrome. Study 5 Retrospective, observational, non-interventional trial to assess safety and efficacy of eculizumab in patients of any age with Atypical Haemolytic Uraemic Syndrome who received at least one

		dose of eculizumab outside an applicant's sponsored controlled trial.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By July 2014
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of Paroxysmal nocturnal haemoglobinuria (PNH)

Authorised indication(s):

Soliris is indicated in adults and children for the treatment of patients with Paroxysmal nocturnal haemoglobinuria (PNH).

Evidence of clinical benefit of Soliris in the treatment of patients with PNH is limited to patients with history of transfusions.

2. Treatment of Atypical haemolytic uremic syndrome (aHUS)

Authorised indication(s):

Soliris is indicated in adults and children for the treatment of patients with Atypical haemolytic uremic syndrome (aHUS).

Authorised pharmaceutical form(s):

Concentrate for solution for infusion

Authorised route(s) of administration:

Intravenous use